Joint pain, fatigue, and flares that strike without warning can make life with psoriatic arthritis challenging. Here's a ...

What lies beneath the surface? Ultrasound is revealing the earliest signs of psoriatic arthritis, and changing care in the ...

Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

Discover how early biologic therapy compares with standard care in psoriatic arthritis. Learn more about treatment strategies ...

P soriatic arthritis is an autoimmune condition where the body’s immune system mistakenly attacks joints and connective tissue. This leads to a cascade of inflammation that causes painful symptoms, ...

Oct. 4, 2013 -- Stelara, an injectable drug already approved to treat psoriasis, is now also approved to treat psoriatic arthritis. Psoriatic arthritis is an autoimmune disease. The immune system ...

Psoriatic arthritis (PsA) has been around for thousands of years. Archaeologists unearthed Egyptian mummies with signs of the disease. Back then, the treatments for swollen and painful joints and red, ...

TREMFYA® (guselkumab) is now clinically proven to protect joints in active psoriatic arthritis, offering durable efficacy and ...

Johnson & Johnson (J&J) has announced new data showing that Tremfya (guselkumab) reduces symptoms of psoriatic arthritis (PsA ...

For Patrice Parker, the road to a psoriatic arthritis (PsA) diagnosis was a bumpy one. Now 34, Parker was diagnosed at age 30—but it took two years to get there. “I would find myself taking longer and ...

New 48-week data from the Phase IIIb APEX trial (NCT04882098) show Tremfya (guselkumab; Johnson & Johnson) produces sustained inhibition of radiographic progression and improved clinical symptoms in ...

In older adults with psoriasis or psoriatic arthritis, use of two biologic classes was associated with lowest rates of serious adverse events than time off those drugs.